Literature DB >> 11704501

Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake.

M M Bliziotes1, A J Eshleman, X W Zhang, K M Wiren.   

Abstract

Neurotransmitter regulation of bone metabolism has been the subject of increasing interest and investigation. Because serotonin (5-HT) plays a role as a regulator of craniofacial morphogenesis, we investigated the expression and function of 5-HT receptors and the 5-HT transporter (5-HTT) in bone. Primary cultures of rat osteoblasts (rOB) and a variety of clonal osteoblastic cell lines, including ROS 17/2.8, UMR 106-H5, and Py1a, showed mRNA expression for 5-HTT as well as the 5-HT(1A), 5-HT(1D), 5-HT(2A), and 5-HT(2B) receptors by reverse transcription-polymerase chain reaction (RT-PCR) analysis. Protein expression of the 5-HT(1A), 5-HT(2A), and 5-HT(2B) receptors was confirmed by immunoblot. 5-HTT binding sites were assessed in ROS 17/2.8 and UMR 106-H5 cells by binding of the stable cocaine analog [125I]RTI-55, which showed a relatively high density of nanomolar affinity binding sites. Imipramine and fluoxetine, antagonists with specificity for 5-HTT, showed the highest potency to antagonize [125I]RTI-55 binding in ROS and UMR cells. GBR-12935, a relatively selective dopamine transporter antagonist, had a much lower potency, as did desipramine, a selective norepinephrine transporter antagonist. The maximal [3H]5-HT uptake rate in ROS cells was 110 pmol/10 min per well, with a K(m) value of 1.13 micromol/L. Imipramine and fluoxetine inhibited specific [3H]5-HT uptake with IC(50) values in the nanomolar range. In normal differentiating rOB cultures, 5-HTT functional activity was observed initially at day 25, and activity increased almost eightfold by day 31. In mature rOB cultures, the estimated density of [125I]RTI-55 binding sites was 600 fmol/mg protein. Functional downregulation of transporter activity was assessed after PMA treatment, which caused a significant 40% reduction in the maximal uptake rate of [3H]5-HT, an effect that was prevented by pretreatment with staurosporine. The affinity of 5-HT for the transporter was significantly increased following PMA treatment. We assessed the functional significance of expression of the 5-HT receptors by investigating the interaction between 5-HT and parathyroid hormone (PTH) signaling. 5-HT potentiates the PTH-induced increase in AP-1 activity in UMR cells. These results demonstrate that osteoblastic cells express a functional serotonin system, with mechanisms for responding to and regulating uptake of 5-HT.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11704501     DOI: 10.1016/s8756-3282(01)00593-2

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  61 in total

1.  Crosstalk between the brain and bone.

Authors:  Laura Masi
Journal:  Clin Cases Miner Bone Metab       Date:  2012-05-29

Review 2.  Minireview: A skeleton in serotonin's closet?

Authors:  Masanobu Kawai; Clifford J Rosen
Journal:  Endocrinology       Date:  2010-07-21       Impact factor: 4.736

3.  Decreased osteoclastogenesis in serotonin-deficient mice.

Authors:  Yasmine Chabbi-Achengli; Amélie E Coudert; Jacques Callebert; Valérie Geoffroy; Francine Côté; Corinne Collet; Marie-Christine de Vernejoul
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

4.  A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys.

Authors:  Chadi A Calarge; Bridget Zimmerman; Diqiong Xie; Samuel Kuperman; Janet A Schlechte
Journal:  J Clin Psychiatry       Date:  2010-03       Impact factor: 4.384

5.  Serotonin transporter and receptor expression in osteocytic MLO-Y4 cells.

Authors:  M Bliziotes; A Eshleman; B Burt-Pichat; X-W Zhang; J Hashimoto; K Wiren; C Chenu
Journal:  Bone       Date:  2006-08-01       Impact factor: 4.398

6.  Possible mechanisms for the skeletal effects of antipsychotics in children and adolescents.

Authors:  Chadi A Calarge; Stephanie D Ivins; Katherine J Motyl; Amal A Shibli-Rahhal; Michael M Bliziotes; Janet A Schlechte
Journal:  Ther Adv Psychopharmacol       Date:  2013-10

7.  Use of anti-depressants and the risk of fracture of the hip or femur.

Authors:  M W M van den Brand; S Pouwels; M M Samson; T P van Staa; B Thio; C Cooper; H G M Leufkens; A C G Egberts; H J J Verhaar; F de Vries
Journal:  Osteoporos Int       Date:  2009-02-24       Impact factor: 4.507

8.  Peripartum dietary supplementation of a small-molecule inhibitor of tryptophan hydroxylase 1 compromises infant, but not maternal, bone.

Authors:  Samantha R Weaver; Hannah P Fricke; Cynthia Xie; Robert J Aiello; Julia F Charles; Laura L Hernandez
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-10-23       Impact factor: 4.310

9.  Dietary tryptophan manipulation reveals a central role for serotonin in the anabolic response of appendicular skeleton to physical activity in rats.

Authors:  Valeria Sibilia; Francesca Pagani; Elisa Dieci; Emanuela Mrak; Marcella Marchese; Guido Zarattini; Francesca Guidobono
Journal:  Endocrine       Date:  2013-04-26       Impact factor: 3.633

10.  Depressive symptoms, bone loss, and fractures in postmenopausal women.

Authors:  Leslie Spangler; Delia Scholes; Robert L Brunner; John Robbins; Susan D Reed; Katherine M Newton; Jennifer L Melville; Andrea Z Lacroix
Journal:  J Gen Intern Med       Date:  2008-02-20       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.